Societal Changes, COVID-19 Among Causes of Oncologist Burnout

News
Video

“Although telehealth is a great thing when used properly, telehealth also puts a barrier between the doctor and the patient,” said Eric P. Winer, MD.

When prompted about the increase in workplace burnout among oncologists, Eric P. Winer, MD, said some contributing factors may be societal changes, the COVID-19 pandemic, and administrative tasks.

CancerNetwork® spoke with Winer following the publication of results from a survey in the Journal of Clinical Oncology that found a 14% increase in oncology burnout from 2013 to 2023. The study results found that being a caregiver in one’s personal life, working more than 60 hours a week, and being younger than 50 years were all associated with burnout (P < .05, respectively).

As for societal changes, Winer alluded to the fact that as more and more clinicians start to seek work-life balance, it may be important to realize that achieving such a thing may be more difficult in medicine. Additionally, the COVID-19 pandemic placed a great deal of stress upon medical professionals, and though it led workers to feel mission driven, many are now dealing with fatigue.

Another large factor he mentioned was the increase in usage of technology and digital screens. Telehealth, for example, though it can be a great thing, puts a barrier between the doctor and the patient. There are also more and more oncologists who must help with tasks such as documentation or insurance authorizations, which many physicians never anticipated having to do.

Winer is the director of Yale Cancer Center, president and physician-in-chief at Smilow Cancer Hospital, deputy dean for cancer research and Alfred Gilman Professor of Pharmacology and Professor of Medicine at Yale School of Medicine, chair of the association board for the American Society of Clinical Oncology, and one of the authors of the survey.

Transcript:

There are a number of factors. One, since I referred to burnout, across the board and in society, some of this is a little bit of a societal issue, because you hear more and more people talking about burnout. You hear more people talking about wanting to achieve a work-life balance, and maybe that’s a little more difficult in medicine than in [other] places, which can lead to burnout. The COVID-19 pandemic was stressful. While on the one hand, early in the pandemic, everyone felt extraordinarily mission driven, as if they were on a battleground, and that tends to bring people together, there’s fatigue associated with that. A lot of people felt that they couldn’t practice the way they would like to practice; they had to make decisions, particularly early on, about treatments that needed to be delayed or not given.

Although telehealth is a great thing when used properly, telehealth also puts a barrier between the doctor and the patient. I will confess to you that I don’t like telehealth. I’m willing to do it occasionally, but I like sitting face-to-face with a patient, and without that, it’s a different interaction. Finally, in the last 10 to 12 years, we’ve seen this proliferation of tasks that many physicians never thought they would have to do: excessive documentation, [spending] all this time in front of screens instead of in front of patients, and insurance authorizations. There are just a lot of pieces of our jobs that don’t feel like they’re mission driven.

Reference

Schenkel C, Levit LA, Kirkwood K, et al. State of professional well-being, satisfaction, and career plans among US oncologists in 2023. J Clin Oncol. Published online January 29, 2025. doi:10.1200/OA.24.00010

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Related Content